Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 321, Issue 3, 2007, Pages 1109-1117

  Pourpak, Alan ^a,b   Landowski, Terry H ^a,b   Dorr, Robert T ^a,b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMONAFIDE; ANTHRACENE DERIVATIVE; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); ETHONAFIDE; MITOXANTRONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL CYCLE ARREST; COMET ASSAY; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; ENZYME INHIBITION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR REGRESSION; XENOGRAFT;

ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DNA BREAKS, DOUBLE-STRANDED; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA, CATENATED; DNA, KINETOPLAST; DNA-BINDING PROTEINS; HUMANS; ISOQUINOLINES; MALE; MELPHALAN; MICE; MICE, SCID; MITOXANTRONE; NAPHTHALIMIDES; PROSTATIC NEOPLASMS; PROTEIN BINDING; QUINOXALINES; RNA INTERFERENCE; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34248578176     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.117457     Document Type: Article

References (40)

1. American Cancer Society (2006) Cancer Facts & Figures 2006, American Cancer Society, Atlanta, GA.
2. Austin CA, and Marsh KL (1998) Eukaryotic DNA topoisomerase II beta. Bioessays 20:215-226.
3. Aviles A, Neri N, Nambo JM, Huerta-Guzman J, Talavera A, and Cleto S (2005) Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy. Leuk Lymphoma 46:1023-1028.
4. Bear S, and Remers WA (1996) Computer simulation of the binding of amonafide and azonafide to DNA. J Comput Aided Mol Des 10:165-175.
5. Bissery MC, Guenard D, Gueritte-Voegelein F, and Lavelle F (1991) Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 51:4845-4852.
6. Champoux JJ (2001) DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 70:369-413.
7. Dignam JD, Lebovitz RM, and Roeder RG (1983) Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 11:1475-1489.
8. Dorr RT, Liddil JD, Sami SM, Remers W, Hersh EM, and Alberts DS (2001) Preclinical antitumor activity of the azonafide series of anthracene-based DNA intercalators. Anticancer Drugs 12:213-220.
9. Emmons M, Boulware D, Sullivan DM, and Hazlehurst LA (2006) Topoisomerase II beta levels are a determinant of melphalan-induced DNA crosslinks and sensitivity to cell death. Biochem Pharmacol 72:11-18.
10. Errington F, Willmore E, Leontiou C, Tilby MJ, and Austin CA (2004) Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity. Cancer Chemother Pharmacol 53:155-162.
11. Errington F, Willmore E, Tilby MJ, Li L, Li G, Li W, Baguley BC, and Austin CA (1999) Murine transgenic cells lacking DNA topoisomerase IIβ are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation. Mol Pharmacol 56:1309-1316.
12. Gao H, Huang KC, Yamasaki EF, Chan KK, Chohan L, and Snapka RM (1999) XK469, a selective topoisomerase IIbeta poison. Proc Natl Acad Sci USA 96: 12168-12173.
13. Grue P, Grasser A, Sehested M, Jensen PB, Uhse A, Straub T, Ness W, and Boege F (1998) Essential mitotic functions of DNA topoisomerase IIα are not adopted by topoisomerase IIbeta in human H69 cells. J Biol Chem 273:33660-33666.
14. Gurumurthy S, Vasudevan KM, and Rangnekar VM (2001) Regulation of apoptosis in prostate cancer. Cancer Metastasis Rev 20:225-243.
15. Hendzel MJ, Wei Y, Mancini MA, Van Hooser A, Ranalli T, Brinkley BR, Bazett-Jones DP, and Allis CD (1997) Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma 106:348-360.
16. Hughes C, Murphy A, Martin C, Fox E, Ring M, Sheils O, Loftus B, and O'Leary J (2006) Topoisomerase II-alpha expression increases with increasing Gleason score and with hormone insensitivity in prostate carcinoma. J Clin Pathol 59:721-724.
17. Innocenti F, Iyer L, and Ratain MJ (2001) Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan. Drug Metab Dispos 29:596-600.
18. Ju BG, Lunyak VV, Perissi V, Garcia-Bassets I, Rose DW, Glass CK, and Rosenfeld MG (2006) A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription. Science (Wash DC) 312:1798-1802.
19. Kent CR, Eady JJ, Ross GM, and Steel GG (1995) The comet moment as a measure of DNA damage in the comet assay. Int J Radiat Biol 67:655-660.
20. 3H-dibenz[de,h] isoquinoline-1,3-diones with substitutions at the 6 and 7 positions (azonafides). Anticancer Drugs 8:245-256.
21. Michels J, Montemurro T, Murray N, Kollmannsberger C, and Nguyen CK (2006) First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter? Cancer 106:1041-1046.
22. Minotti G, Menna P, Salvatorelli E, Cairo G, and Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185-229.
23. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63.
24. Nakamura K, Sugumi H, Yamaguchi A, Uenaka T, Kotake Y, Okada T, Kamata J, Niijima J, Nagasu T, Koyanagi N, et al. (2002) Antitumor activity of ER-37328, a novel carbazole topoisomerase II inhibitor. Mol Cancer Ther 1:169-175.
25. Oshiro MM, Landowski TH, Catlett-Falcone R, Hazlehurst LA, Huang M, Jove R, and Dalton WS (2001) Inhibition of JAK kinase activity enhances Fas-mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells. Clin Cancer Res 7:4262-4271.
26. 3H-dibenz[de-,h]isoquinoline-1,3diones. Curr Top Med Chem 2:45-61.
27. Sakaguchi A, and Kikuchi A (2004) Functional compatibility between isoform alpha and beta of type II DNA topoisomerase. J Cell Sci 117:1047-1054.
28. 3H-dibenz[de,h] isoquinoline-1,3diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships. J Med Chem 39:1609-1618.
29. Skoufias DA, Lacroix FB, Andreassen PR, Wilson L, and Margolis RL (2004) Inhibition of DNA decatenation, but not DNA damage, arrests cells at metaphase. Mol Cell 15:977-990.
30. Snapka RM, Gao H, Grabowski DR, Brill D, Chan KK, Li L, Li GC, and Ganapathi R (2001) Cytotoxic mechanism of XK469: resistance of topoisomerase IIbeta knockout cells and inhibition of topoisomerase I. Biochem Biophys Res Commun 280: 1155-1160.
31. Sobel RE, and Sadar MD (2005) Cell lines used in prostate cancer research: a compendium of old and new lines-part 1. J Urol 173:342-359.
32. Sugimoto K, Yamada K, Egashira M, Yazaki Y, Hirai H, Kikuchi A, and Oshimi K (1998) Temporal and spatial distribution of DNA topoisomerase II alters during proliferation, differentiation, and apoptosis in HL-60 cells. Blood 91:1407-1417.
33. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512.
34. Trojan L, Kiknavelidze K, Knoll T, Alken P, and Michel MS (2005) Prostate cancer therapy: standard management, new options and experimental approaches. Anticancer Res 25:551-561.
35. Turley H, Comley M, Houlbrook S, Nozaki N, Kikuchi A, Hickson ID, Gatter K, and Harris AL (1997) The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues. Br J Cancer 75:1340-1346.
36. Valkov NI, and Sullivan DM (2003) Tumor p53 status and response to topoisomerase II inhibitors. Drug Resist Updat 6:27-39.
37. van Brussel JP, and Mickisch GH (2003) Multidrug resistance in prostate cancer. Onkologie 26:175-181.
38. van Brussel JP, van Steenbrugge GJ, Romijn JC, Schroder FH, and Mickisch GH (1999) Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins. Eur J Cancer 35:664-671.
39. Vogel C, Kienitz A, Muller R, and Bastians H (2005) The mitotic spindle checkpoint is a critical determinant for topoisomerase-based chemotherapy. J Biol Chem 280:4025-4028.
40. Walker JV, and Nitiss JL (2002) DNA topoisomerase II as a target for cancer chemotherapy. Cancer Investig 20:570-589.